PE20142301A1 - Uracilos sustituidos biciclicamente y uso de los mismos - Google Patents
Uracilos sustituidos biciclicamente y uso de los mismosInfo
- Publication number
- PE20142301A1 PE20142301A1 PE2014001986A PE2014001986A PE20142301A1 PE 20142301 A1 PE20142301 A1 PE 20142301A1 PE 2014001986 A PE2014001986 A PE 2014001986A PE 2014001986 A PE2014001986 A PE 2014001986A PE 20142301 A1 PE20142301 A1 PE 20142301A1
- Authority
- PE
- Peru
- Prior art keywords
- bicyclically
- uracilos
- replaced
- same
- compounds
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Abstract
SE REFIERE A COMPUESTOS DERIVADOS DE URACILO SUSTITUIDOS BICICLICAMENTE DE FORMULA (I) DONDE R1, R2 Y R3 SON COMO SE DEFINEN EN LA PRESENTE. SON COMPUESTOS PREFERIDOS: 3-[2-CLORO-3-(TRIFLUOROMETIL)BENCIL]-1-(3-(CICLOPROPILMETIL)-1-METIL-2-OXO-2,3-DIHIDRO-1H-BENCIMIDAZOL-5-IL)-2,4-DIOXO-1,2,3,4-TETRAHIDROPIRIMIDINA-5-CARBOXILATO DE ETILO; 3-[2-CLORO-3-(TRIFLUOROMETIL)BENCIL]-1-(1-METIL-3-(OXETAN-2-ILMETIL)-2-OXO-2,3-DIHIDRO-1H-BENCIMIDAZOL-5-IL)-2,4-DIOXO-1,2,3,4-TETRAHIDROPIRIMIDINA-5-CARBOXILATO DE ETILO; ENTRE OTROS. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA Y A PROCEDIMIENTOS DE PREPARACION. DICHOS COMPUESTOS SON INHIBIDORES DE QUINASA UTILES PARA EL TRATAMIENTO DE INSUFICIENCIA CARDIACA, HIPERTENSION PULMONAR, ASMA
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP12167231 | 2012-05-09 |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20142301A1 true PE20142301A1 (es) | 2014-12-19 |
Family
ID=48289199
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2014001986A PE20142301A1 (es) | 2012-05-09 | 2013-05-03 | Uracilos sustituidos biciclicamente y uso de los mismos |
Country Status (44)
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
UA112897C2 (uk) * | 2012-05-09 | 2016-11-10 | Байєр Фарма Акцієнгезелльшафт | Біциклічно заміщені урацили та їх застосування для лікування і/або профілактики захворювань |
EP3066095A1 (de) * | 2013-11-08 | 2016-09-14 | Bayer Pharma Aktiengesellschaft | Substituierte 1,2,4-triazin-3,5-dione und ihre verwendung als chymase hemmern |
CN105658647B (zh) * | 2013-11-08 | 2019-09-06 | 拜耳医药股份有限公司 | 化合物的盐 |
EP3066098A1 (de) | 2013-11-08 | 2016-09-14 | Bayer Pharma Aktiengesellschaft | Substituierte uracile und ihre verwendung |
CN105873919A (zh) * | 2013-11-08 | 2016-08-17 | 拜耳医药股份有限公司 | 作为类糜蛋白酶抑制剂的取代的尿嘧啶 |
WO2017162661A1 (en) | 2016-03-22 | 2017-09-28 | Bayer Pharma Aktiengesellschaft | 1h-benzo[de]isoquinoline-1,3(2h)-diones |
EP3338780A1 (de) * | 2016-12-20 | 2018-06-27 | Bayer Pharma Aktiengesellschaft | Verwendung von chymaseinhibitoren zur behandlung von endometriose, post-operativer fibrose und erkrankungen die durch fibrosebildung gekennzeichnet sind |
EP3615031A1 (en) | 2017-04-27 | 2020-03-04 | Bayer Aktiengesellschaft | Selective adrenoreceptor alpha2c receptor antagonists alone, or in combination with chymase inhibitors for use in the treatment and/or prophylaxis of peripheral artery diseases (pad) |
SG11202011018PA (en) | 2018-05-15 | 2020-12-30 | Bayer Ag | 1,3-thiazol-2-yl substituted benzamides for the treatment of diseases associated with nerve fiber sensitization |
CN110229067A (zh) * | 2019-06-05 | 2019-09-13 | 南京焕然生物科技有限公司 | 一种2-氨基茚制备方法 |
WO2021000933A1 (zh) * | 2019-07-03 | 2021-01-07 | 南京明德新药研发有限公司 | 作为糜酶抑制剂的嘧啶酮类化合物及其应用 |
CN111440141A (zh) * | 2020-05-20 | 2020-07-24 | 安徽泽升科技有限公司 | 一种羟甲基取代芳杂环类化合物的制备方法 |
CN114671856B (zh) * | 2020-12-25 | 2023-10-20 | 广东东阳光药业股份有限公司 | 多取代的尿嘧啶衍生物及其用途 |
WO2022135514A1 (zh) * | 2020-12-25 | 2022-06-30 | 广东东阳光药业有限公司 | 多取代的尿嘧啶衍生物及其用途 |
CN114671878B (zh) * | 2020-12-25 | 2023-08-04 | 广东东阳光药业有限公司 | 取代的含氮双环化合物及其用途 |
TW202339706A (zh) * | 2021-12-06 | 2023-10-16 | 美商普萊萃歐治療公司 | 含醯胺的lonp1抑制劑化合物、用途及方法 |
US11618751B1 (en) | 2022-03-25 | 2023-04-04 | Ventus Therapeutics U.S., Inc. | Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 derivatives |
WO2023194222A1 (en) * | 2022-04-05 | 2023-10-12 | Socpra Sciences Santé Humaines S.E.C. | Inhibitors of chymase for use in the selective resolution of thrombi in thrombotic or thromboembolic disorders |
Family Cites Families (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6403599B1 (en) * | 1995-11-08 | 2002-06-11 | Pfizer Inc | Corticotropin releasing factor antagonists |
US6114532A (en) | 1998-02-03 | 2000-09-05 | Boehringer Ingelheim Pharma Kg | Bicyclic heterocycles, the preparation thereof, and their use as pharmaceuticals |
DE19834044A1 (de) | 1998-07-29 | 2000-02-03 | Bayer Ag | Neue substituierte Pyrazolderivate |
DE19834047A1 (de) | 1998-07-29 | 2000-02-03 | Bayer Ag | Substituierte Pyrazolderivate |
US6458952B1 (en) | 1999-05-19 | 2002-10-01 | Pharmacia Corporation | Substituted polycyclic aryl and heteroaryl uracils useful for selective inhibition of the coagulation cascade |
WO2001017980A1 (fr) | 1999-09-03 | 2001-03-15 | Ajinomoto Co., Inc. | Nouveaux procedes de preparation de derives d'oxazepine |
DE19943635A1 (de) | 1999-09-13 | 2001-03-15 | Bayer Ag | Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften |
DE19943639A1 (de) | 1999-09-13 | 2001-03-15 | Bayer Ag | Dicarbonsäurederivate mit neuartigen pharmazeutischen Eigenschaften |
DE19943634A1 (de) | 1999-09-13 | 2001-04-12 | Bayer Ag | Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften |
DE19943636A1 (de) | 1999-09-13 | 2001-03-15 | Bayer Ag | Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften |
GB0021315D0 (en) * | 2000-08-30 | 2000-10-18 | Dainippon Pharmaceutical Co | Heterocyclic compounds and intermediates thereof |
AR031176A1 (es) | 2000-11-22 | 2003-09-10 | Bayer Ag | Nuevos derivados de pirazolpiridina sustituidos con piridina |
DE10110750A1 (de) | 2001-03-07 | 2002-09-12 | Bayer Ag | Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften |
DE10110749A1 (de) | 2001-03-07 | 2002-09-12 | Bayer Ag | Substituierte Aminodicarbonsäurederivate |
JP2003017508A (ja) | 2001-07-05 | 2003-01-17 | Nec Corp | 電界効果トランジスタ |
AR038536A1 (es) | 2002-02-25 | 2005-01-19 | Upjohn Co | N-aril-2-oxazolidinona-5- carboxamidas y sus derivados |
DE10220570A1 (de) | 2002-05-08 | 2003-11-20 | Bayer Ag | Carbamat-substituierte Pyrazolopyridine |
JP2003342265A (ja) * | 2002-05-22 | 2003-12-03 | Senju Pharmaceut Co Ltd | トリアゾリジン誘導体およびその医薬用途 |
AU2003290735A1 (en) | 2002-12-06 | 2004-06-30 | Eli Lilly And Company | Inhibitors of monoamine uptake |
JP4387360B2 (ja) * | 2003-08-22 | 2009-12-16 | 帝人ファーマ株式会社 | キマーゼ阻害剤を有効成分として含有する薬剤 |
DE102004004928A1 (de) | 2004-01-31 | 2005-08-18 | Bayer Healthcare Ag | Dibenzoxazepine II |
AU2005225471B2 (en) | 2004-03-26 | 2011-05-12 | Methylgene Inc. | Inhibitors of histone deacetylase |
US7507748B2 (en) | 2004-07-22 | 2009-03-24 | Amgen Inc. | Substituted aryl-amine derivatives and methods of use |
JP5197016B2 (ja) | 2004-12-23 | 2013-05-15 | デシファラ ファーマスーティカルズ, エルエルシー | 酵素モジュレータ及び治療 |
WO2006119504A2 (en) | 2005-05-04 | 2006-11-09 | Renovis, Inc. | Fused heterocyclic compounds, and compositions and uses thereof |
WO2007007161A2 (en) * | 2005-07-08 | 2007-01-18 | Orchid Research Laboratories Limited | Novel bio-active derivatives |
EP1968950A4 (en) | 2005-12-19 | 2010-04-28 | Genentech Inc | PYRIMIDINKINASEINHIBITOREN |
CA2642406A1 (en) | 2006-02-14 | 2007-08-23 | Pfizer Products Inc. | Benzoxazinone and benzoxazepinone oxazolidinones as antibacterial agents |
TWI394747B (zh) * | 2006-06-23 | 2013-05-01 | Smithkline Beecham Corp | 脯胺醯基羥化酶抑制劑 |
US7790756B2 (en) | 2006-10-11 | 2010-09-07 | Deciphera Pharmaceuticals, Llc | Kinase inhibitors useful for the treatment of myleoproliferative diseases and other proliferative diseases |
GB0622472D0 (en) | 2006-11-10 | 2006-12-20 | Addex Pharmaceuticals Sa | Novel heterocyclic derivatives |
WO2008103277A2 (en) | 2007-02-16 | 2008-08-28 | Amgen Inc. | Nitrogen-containing heterocyclyl ketones and their use as c-met inhibitors |
CA2683785A1 (en) | 2007-04-13 | 2008-10-23 | Vertex Pharmaceuticals Incorporated | Aminopyrimidines useful as kinase inhibitors |
WO2009049112A1 (en) | 2007-10-10 | 2009-04-16 | Smithkline Beecham Corporation | Prolyl hydroxylase inhibitors |
KR20100075930A (ko) | 2007-10-19 | 2010-07-05 | 베링거 인겔하임 인터내셔날 게엠베하 | 헤테로사이클-치환된 피페라지노-디하이드로티에노피리미딘 |
MX2010012067A (es) * | 2008-05-05 | 2010-12-06 | Merck Frosst Canada Ltd | Derivados de 3,4-piperidina sustituida como inhibidores de la renina. |
DE102008030091B4 (de) * | 2008-06-25 | 2011-03-03 | Resprotect Gmbh | Uracilderivate und deren Verwendung |
NZ588983A (en) | 2008-06-25 | 2011-11-25 | Daiichi Sankyo Co Ltd | Carboxylic acid compound |
UA112897C2 (uk) * | 2012-05-09 | 2016-11-10 | Байєр Фарма Акцієнгезелльшафт | Біциклічно заміщені урацили та їх застосування для лікування і/або профілактики захворювань |
-
2013
- 2013-03-05 UA UAA201413167A patent/UA112897C2/uk unknown
- 2013-05-03 DK DK16154186.7T patent/DK3045456T3/da active
- 2013-05-03 PL PL16154186T patent/PL3045456T3/pl unknown
- 2013-05-03 SG SG10202003175QA patent/SG10202003175QA/en unknown
- 2013-05-03 PE PE2014001986A patent/PE20142301A1/es active IP Right Grant
- 2013-05-03 RS RS20180076A patent/RS56784B1/sr unknown
- 2013-05-03 CN CN201710219097.9A patent/CN106983751B/zh active Active
- 2013-05-03 RS RS20160510A patent/RS54901B1/sr unknown
- 2013-05-03 PT PT161541867T patent/PT3045456T/pt unknown
- 2013-05-03 CA CA2872906A patent/CA2872906C/en active Active
- 2013-05-03 SI SI201330934T patent/SI3045456T1/en unknown
- 2013-05-03 PL PL13720407.9T patent/PL2847190T3/pl unknown
- 2013-05-03 HU HUE13720407A patent/HUE029366T2/en unknown
- 2013-05-03 AP AP2014008096A patent/AP2014008096A0/xx unknown
- 2013-05-03 WO PCT/EP2013/059286 patent/WO2013167495A1/de active Application Filing
- 2013-05-03 AU AU2013258223A patent/AU2013258223B2/en active Active
- 2013-05-03 MX MX2018008811A patent/MX367599B/es unknown
- 2013-05-03 EP EP16154186.7A patent/EP3045456B1/de active Active
- 2013-05-03 MY MYPI2014703273A patent/MY181828A/en unknown
- 2013-05-03 MX MX2014013571A patent/MX357712B/es active IP Right Grant
- 2013-05-03 KR KR1020147034155A patent/KR102083281B1/ko active IP Right Grant
- 2013-05-03 LT LTEP16154186.7T patent/LT3045456T/lt unknown
- 2013-05-03 PT PT137204079T patent/PT2847190T/pt unknown
- 2013-05-03 EA EA201492040A patent/EA030383B9/ru not_active IP Right Cessation
- 2013-05-03 SI SI201330233A patent/SI2847190T1/sl unknown
- 2013-05-03 BR BR112014028086-0A patent/BR112014028086B1/pt active IP Right Grant
- 2013-05-03 CN CN201380034776.9A patent/CN104395310B/zh active Active
- 2013-05-03 DK DK13720407.9T patent/DK2847190T3/en active
- 2013-05-03 US US14/399,945 patent/US9481672B2/en active Active
- 2013-05-03 ES ES13720407.9T patent/ES2581537T3/es active Active
- 2013-05-03 EP EP13720407.9A patent/EP2847190B1/de active Active
- 2013-05-03 HU HUE16154186A patent/HUE035462T2/en unknown
- 2013-05-03 NO NO16154186A patent/NO3045456T3/no unknown
- 2013-05-03 ES ES16154186.7T patent/ES2657315T3/es active Active
- 2013-05-03 NZ NZ701700A patent/NZ701700A/en unknown
- 2013-05-03 EA EA201790032A patent/EA031222B1/ru not_active IP Right Cessation
- 2013-05-03 JP JP2015510754A patent/JP6141414B2/ja active Active
- 2013-05-08 TW TW102116308A patent/TWI579278B/zh active
- 2013-05-08 SA SA113340533A patent/SA113340533B1/ar unknown
- 2013-05-08 AR ARP130101600A patent/AR090994A1/es active IP Right Grant
- 2013-05-08 JO JOP/2013/0144A patent/JO3290B1/ar active
- 2013-05-08 UY UY0001034797A patent/UY34797A/es active IP Right Grant
- 2013-05-08 TW TW106105676A patent/TWI635085B/zh active
-
2014
- 2014-11-02 IL IL235438A patent/IL235438A/en active IP Right Grant
- 2014-11-06 CU CU2014000129A patent/CU20140129A7/es unknown
- 2014-11-07 EC ECIEPI201426138A patent/ECSP14026138A/es unknown
- 2014-11-07 TN TN2014000470A patent/TN2014000470A1/fr unknown
- 2014-11-07 PH PH12014502496A patent/PH12014502496B1/en unknown
- 2014-11-07 CL CL2014003031A patent/CL2014003031A1/es unknown
- 2014-11-07 ZA ZA2014/08146A patent/ZA201408146B/en unknown
- 2014-11-07 CR CR20140513A patent/CR20140513A/es unknown
- 2014-11-07 DO DO2014000255A patent/DOP2014000255A/es unknown
- 2014-11-07 CO CO14246970A patent/CO7131375A2/es unknown
-
2015
- 2015-04-09 HK HK15103474.2A patent/HK1202873A1/xx unknown
-
2016
- 2016-07-06 CY CY20161100636T patent/CY1118900T1/el unknown
- 2016-07-06 HR HRP20160796TT patent/HRP20160796T1/hr unknown
- 2016-10-07 US US15/288,982 patent/US9949978B2/en active Active
- 2016-10-07 US US15/288,968 patent/US9949977B2/en active Active
-
2017
- 2017-05-02 JP JP2017091842A patent/JP6367421B2/ja active Active
- 2017-08-10 IL IL253950A patent/IL253950B/en active IP Right Grant
- 2017-11-22 AU AU2017265047A patent/AU2017265047B2/en active Active
-
2018
- 2018-01-23 HR HRP20180125TT patent/HRP20180125T1/hr unknown
- 2018-01-24 CY CY20181100095T patent/CY1119840T1/el unknown
- 2018-03-05 US US15/912,185 patent/US10300062B2/en active Active
-
2019
- 2019-04-02 US US16/373,487 patent/US20200061063A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20142301A1 (es) | Uracilos sustituidos biciclicamente y uso de los mismos | |
PE20121050A1 (es) | Compuestos de n-(1-(4-(1h-pirazol-5-il)ftalazin-1-il)piperidin-4-il)-benzamida sustituidos como antagonistas de la trayectoria hedgehog | |
EA201290940A1 (ru) | Новые соединения как селективные антагонисты рецептора nk3, фармацевтическая композиция и методы их использования при нарушениях, опосредованных nk3 рецепторами | |
CL2013000104A1 (es) | Compuestos derivados de heterociclicos nitrogenados sustituidos, agonistas del receptor ip; composicion farmaceutica; combinación farmaceutica; y uso para el tratamiento de la hipertension arterial pulmonar. | |
DE602008002934D1 (de) | 2-cyclopropylthiazolderivate | |
PE20170502A1 (es) | ACIDO 4-(3-FLUORO-3-(2-(5,6,7,8-TETRAHIDRO-1,8-NAFTIRIDIN-2-IL)ETIL)PIRROLIDIN-1-IL)-3-(3-(2-METOXIETOXI)FENIL)BUTANOICO COMO ANTAGONISTA DE INTEGRINA aVß6 | |
UY31124A1 (es) | Derivados de oxiadazol y su uso como potenciadores del receptor metabotropico de glutamato - 842 | |
CY1117745T1 (el) | Ετεροκυκλικες ενωσεις και χρηση αυτων ως ρυθμιστες υποδοχεα τυπου iii κινασων τυροσινης | |
CU20100159A7 (es) | Compuestos | |
UY31127A1 (es) | Ligandos de oxiadazol del receptor metabotropico para el glutamato y su utilizacion como potenciadores - 841 | |
PE20141682A1 (es) | Derivados de (4-fenilimidazol-2-il) etilamina utiles como moduladores de canal de sodio | |
EA201590873A1 (ru) | Соединения, обладающие активностью антагонистов мускариновых рецепторов и агонистов бета2 адренергических рецепторов | |
UY32296A (es) | Nuevos compuestos | |
PE20091565A1 (es) | Derivados de 2-pirazinona como inhibidores de la elastasa de los neutrofilos | |
NO20085257L (no) | Purinonderivater som HM74a-agonister | |
EA201100161A1 (ru) | Производные хинуклидина карбоната и их медицинские композиции | |
CL2007002689A1 (es) | Compuestos derivados de piperidin-1-carboxamida, inhibidores de la renina; compuestos intermediarios; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como hipertension, insuficiencia cardiaca, fibrosis cardiaca, entre otras. | |
PE20140934A1 (es) | Derivados de pirazol | |
PE20160846A1 (es) | Piperidiniltetrahidroquinolinas sustituidas y su uso como antagonistas de los adenoreceptores alpha-2c | |
EA201100612A1 (ru) | Новые производные 2-амидотиадиазола | |
CO6361924A2 (es) | Nuevas lactamas como inhibidores de beta secretasa | |
MX2013002329A (es) | Agonista de receptores de neutrofina y sus usos como medicamentos. | |
PH12014501415A1 (en) | Heterocyclic amide derivatives as p2x7 receptor antagonists | |
CL2010001459A1 (es) | Compuesto derivados de benzoxazinona; compuesto intermediarios; composicion y combinacion farmaceutica; y uso para el trratamiento de enfermedades tales como insuficiencia respiratoria en el adulto, enfisema pulmonar, bronquitis, epoc, entre otras. | |
EA201590823A1 (ru) | 6-((s)-1-{1-[5-(2-гидроксиэтокси)пиридин-2-ил]-1h-пиразол-3-ил}этил)-3h-1,3-бензотиазол-2-он в качестве антагониста tarp-гамма 8-зависимого ampa-рецептора |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant, registration |